Business Description
Lee's Pharmaceutical Holdings Ltd
NAICS : 325412
ISIN : KYG5438W1116
Compare
Compare
Traded in other countries / regions
00950.Hong KongL1PA.GermanyLPCUF.USA IPO Date
2002-07-15Description
Lee's Pharmaceutical Holdings Ltd is a Cayman Island-based research-driven and market-oriented biopharmaceutical company. It is integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales, and marketing in China with global perspectives. It focuses on cardiovascular, woman's health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. Its portfolio has two categories of Proprietary products and Licensed-in products. Its maximum revenue is generated from China. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Eyprotor. Its Licensed-in Products include Carnitene, Ferplex, ALOXI, and Centraxal Plus, among others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.84 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | 10.64 | |||||
| Interest Coverage | 14.13 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.49 | |||||
| Beneish M-Score | -2.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.6 | |||||
| 3-Year EBITDA Growth Rate | 0.8 | |||||
| 3-Year EPS without NRI Growth Rate | -26.4 | |||||
| 3-Year FCF Growth Rate | 21.1 | |||||
| 3-Year Book Growth Rate | -5.8 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.75 | |||||
| 9-Day RSI | 33.02 | |||||
| 14-Day RSI | 35.43 | |||||
| 6-1 Month Momentum % | -1.57 | |||||
| 12-1 Month Momentum % | -14.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.01 | |||||
| Quick Ratio | 0.55 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 456.13 | |||||
| Days Sales Outstanding | 65.82 | |||||
| Days Payable | 152 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.55 | |||||
| 3-Year Dividend Growth Rate | -26.2 | |||||
| Forward Dividend Yield % | 1.72 | |||||
| 5-Year Yield-on-Cost % | 0.56 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 11.56 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.15 | |||||
| Operating Margin % | 7.55 | |||||
| Net Margin % | 3.91 | |||||
| ROE % | 1.15 | |||||
| ROA % | 0.8 | |||||
| ROIC % | 2.24 | |||||
| ROC (Joel Greenblatt) % | 3.89 | |||||
| ROCE % | 0.88 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.74 | |||||
| PE Ratio without NRI | 29.74 | |||||
| PEG Ratio | 3.72 | |||||
| PS Ratio | 1.17 | |||||
| PB Ratio | 0.34 | |||||
| Price-to-Tangible-Book | 0.71 | |||||
| Price-to-Operating-Cash-Flow | 2.41 | |||||
| EV-to-EBIT | 37.33 | |||||
| EV-to-EBITDA | 37.33 | |||||
| EV-to-Revenue | 1.23 | |||||
| EV-to-FCF | 10.26 | |||||
| Price-to-Projected-FCF | 0.42 | |||||
| Price-to-DCF (Earnings Based) | 2.58 | |||||
| Price-to-Median-PS-Value | 0.32 | |||||
| Price-to-Graham-Number | 0.97 | |||||
| Earnings Yield (Greenblatt) % | 2.68 | |||||
| Forward Rate of Return (Yacktman) % | 6.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lee's Pharmaceutical Holdings Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 583.982 | ||
| EPS (TTM) (HK$) | 0.039 | ||
| Beta | 0.63 | ||
| Volatility % | 37.75 | ||
| 14-Day RSI | 35.43 | ||
| 14-Day ATR (HK$) | 0.041122 | ||
| 20-Day SMA (HK$) | 1.2085 | ||
| 12-1 Month Momentum % | -14.38 | ||
| 52-Week Range (HK$) | 1.12 - 1.75 | ||
| Shares Outstanding (Mil) | 588.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lee's Pharmaceutical Holdings Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lee's Pharmaceutical Holdings Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lee's Pharmaceutical Holdings Ltd Frequently Asked Questions
What is Lee's Pharmaceutical Holdings Ltd(HKSE:00950)'s stock price today?
The current price of HKSE:00950 is HK$1.16. The 52 week high of HKSE:00950 is HK$1.75 and 52 week low is HK$1.12.
When is next earnings date of Lee's Pharmaceutical Holdings Ltd(HKSE:00950)?
The next earnings date of Lee's Pharmaceutical Holdings Ltd(HKSE:00950) is .
Does Lee's Pharmaceutical Holdings Ltd(HKSE:00950) pay dividends? If so, how much?
The Dividend Yield %  of Lee's Pharmaceutical Holdings Ltd(HKSE:00950) is 1.55% (As of Today), Highest Dividend Payout Ratio of Lee's Pharmaceutical Holdings Ltd(HKSE:00950) was 0.31. The lowest was 0.02. And the median was 0.28. The  Forward Dividend Yield % of Lee's Pharmaceutical Holdings Ltd(HKSE:00950) is 1.72%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers